Posted by Michael Wonder on 22 Dec 2020
FDA approves Kineret (anakinra) for the treatment of deficiency of IL-1 receptor antagonist
22 December 2020 - DIRA is an ultra-rare, auto-inflammatory disease that typically presents in infancy and is characterised by life-threatening and painful skin and bone inflammation, intense, chronic pain and stunted growth.
Sobi announced that the U.S. FDA has approved the supplemental biologics license application for Kineret (anakinra) for the treatment of deficiency of IL-1 receptor antagonist (DIRA).
